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Abstract: Clinical guidelines now recognize the importance of a multifactorial approach to 
managing cardiovascular (CV) risk. This idea was taken a step further with the concept of 
the Polypill™. There are, however, considerable patent, pharmacokinetic, pharmacodynamic, 
registration, and cost implications that will need to be overcome before the Polypill™ or other 
single-pill combinations of CV medications become widely available. However, a medication 
targeting blood pressure (BP) and lipids provides much of the proposed benefits of the Polypill™. 
A single-pill combination of the antihypertensive amlodipine besylate and the lipid-lowering 
medication atorvastatin calcium (SPAA) is currently available in many parts of the world. This 
review describes the rationale for this combination therapy and the clinical trials that have 
demonstrated that these two agents can be combined without the loss of efficacy for either agent 
or an increase in the incidence of adverse events. The recently completed Cluster Randomized 
Usual Care vs Caduet Investigation Assessing Long-term-risk (CRUCIAL trial) is discussed in 
detail. CRUCIAL was a 12-month, international, multicenter, prospective, open-label, parallel 
design, cluster-randomized trial, which demonstrated that a proactive intervention strategy based 
on SPAA in addition to usual care (UC) had substantial benefits on estimated CV risk, BP, and 
lipids over continued UC alone. Adherence with antihypertensive and lipid-lowering therapies 
outside of the controlled environment of clinical trials is very low (∼30%–40% at 12 months). 
Observational studies have demonstrated that improving adherence to lipid-lowering and anti-
hypertensive medications may reduce CV events. One means of improving adherence is the use 
of single-pill combinations. Real-world observational studies have demonstrated that patients 
are more adherent to SPAA than co-administered antihypertensive and lipid-lowering therapy, 
and this improved adherence translated to reduced CV events. Taken together, these findings 
suggest that SPAA can play an important role in helping physicians improve the management 
of CV risk in their patients.
Keywords: Polypill™, multifactorial management, cardiovascular risk, single-pill amlodipine 
atorvastatin, CRUCIAL study, adherence
Introduction
Cardiovascular disease (CVD) has a multifactorial nature with CV risk factors rarely 
occurring in isolation.1–3 Indeed, the combination of certain risk factors such as hyper-
tension (HTN) and dyslipidemia (DYS) can act multiplicatively or synergistically to 
increase the risk of CVD events.4–6 This synergistic relationship is recognized by most 
of the major clinical guidelines used currently to aid the management of patients with 
symptomatic CVD or at risk of CVD, as they recommend a strategy of treating CVD 
risk factors simultaneously rather than in isolation.7–10 There is an ever-increasing 
body of evidence describing the advantages of a combined/multifactorial approach to Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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reducing CV risk vs the older sequential approach of treating 
risk factors individually.11–16
This multifactorial approach to CV risk reduction was 
taken a stage further by Wald and Law in 200313 with the 
suggestion that a combination pill containing a statin, three 
different antihypertensives (each at half of the standard 
dose), folic acid, and aspirin could reduce CVD risk by 
more than 80%. In the 8 years since this paper was pub-
lished, various pilot studies and Phase II trials of other sin-
gle-pill combinations of antihypertensives, lipid-lowering 
medications, and aspirin (eg, the Polycap, which contains 
low doses of thiazide, atenolol, ramipril, simvastatin, and 
aspirin) have been completed and published.17–19 While the 
results of some of these studies have been promising, such 
as the Phase II study of the Polycap,17 in other studies the 
estimated reductions in CVD risk with single-pill combina-
tions of CV medications have not been as large as those 
originally estimated by Wald and Law.13,19 Furthermore, 
there are significant patent, potential pharmacokinetic, 
pharmacodynamic, registration, and cost implications 
that will need to be overcome before the PolypillTM 20 or 
other single-pill combinations of CV medications are 
approved for use by regulators and become available for 
general use.
A large proportion of the proposed CV benefits of the 
PolypillTM were achieved by targeting HTN and DYS; using 
the information published in Table 1 of the original Wald 
and Law paper,13 simple calculations demonstrate that the 
  majority (90%) of the proposed 88% benefit of the PolypillTM 
on ischemic heart disease and 88% of the proposed 80% 
stroke benefit was due to the use of multiple antihyperten-
sives at low doses and the low dose of a single lipid-lowering 
agent.13 A single-pill combination of the antihypertensive 
amlodipine besylate and the lipid-lowering agent atorvastatin 
calcium (single-pill amlodipine/atorvastatin [SPAA]), has 
been available in the USA since 2004 and in other parts of 
the world since 2005.
The remainder of this review will discuss the rationale 
for combining amlodipine and atorvastatin, and discusses the 
results of a wide array of preclinical, clinical, and real-world 
observational studies assessing the efficacy, safety, and utility 
of the SPAA combination. The Cluster Randomized Usual 
Care vs Caduet Investigation Assessing Long-term-risk 
(CRUCIAL trial) will be discussed in detail (Figure 1). This 
trial is the most recent and longest clinical study of SPAA.21 
Earlier SPAA studies have been discussed in detail in earlier 
reviews,22–24 so they will not be detailed extensively in this 
paper. This review will instead focus on the CRUCIAL trial 
and the recent health economic and outcomes research studies 
that were not covered in the earlier reviews.
Rationale for the combination  
of amlodipine and atorvastatin
One of the driving forces for the development of the 
PolypillTM was the poor level of control of CV risk factors, 
despite the widespread availability of efficacious antihyper-
tensive and lipid-lowering mediations.25–27 For example, The 
European Action on Secondary and Primary Prevention by 
Intervention to Reduce Events III (EUROASPIRE III) survey 
carried out in 2006–2007 across 22 countries in Europe26 
showed that 56% of patients with symptomatic CVD were not 
reaching their assigned 2007 European Society of Cardiology 
(ESC) blood pressure (BP) targets9 and over half of patients 
remained above the recommended ESC lipid targets. The 
poor level of control of HTN and DYS highlights the need 
for new strategies to manage these (and other) risk factors 
thereby reducing the impact of CVD. A single-pill combina-
tion of an antihypertensive and lipid-lowering medication 
may address some of the issues thought to hinder the manage-
ment of CVD, such as poor adherence to multiple treatments 
due to high pill burden and the reluctance of physicians to 
manage more than one CV risk factor simultaneously.
The agents used in a combination medication for the 
treatment of HTN and DYS should have proven efficacy 
and excellent tolerability profiles. The antihypertensive 
component(s) should also be free from drug–drug inter-
actions with other BP-lowering medications due to the 
frequent need for multiple antihypertensives to achieve 
BP goals in certain difficult-to-treat populations, such 
as patients with diabetes. The antihypertensive amlo-
dipine besylate fulfills these criteria in that it has been 
demonstrated to reduce CV events in different patient 
populations28–30 and is effective when combined with 
other classes of antihypertensive.31 Amlodipine besylate 
is a dihydropyridine calcium channel antagonist (calcium 
channel blocker [CCB]) that primarily inhibits calcium 
ion influx into cardiac and smooth muscle cells, resulting 
in peripheral arterial vasodilation and a reduction in BP.32 
The lipid-lowering agent atorvastatin calcium has also 
been demonstrated to reduce CV events in a variety of 
different patient populations (including those with HTN 
and $3 additional CV risk factors).12,14,33 Atorvastatin is 
a selective inhibitor of HMG-CoA reductase, the enzyme 
that converts 3-hydroxy-3-methylglutaryl-coenzyme A to 
mevalonate, a precursor of cholesterol and lipoproteins, 
and thereby reduces the formation of lipids.34Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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.Integrated Blood Pressure Control 2011:4
Primary efficacy assessment:
Framingham 10-year risk of total CHD at week 52
Secondary efficacy assessments:
Framingham 10-year risk of total CHD at week 16
SCORE 10-year risk of CV mortality at weeks 16 and 52
Framingham 10-year risk of fatal and non-fatal CVD at weeks 16 and 52
Framingham stroke risk at weeks 16 and 52
BP/LDL-C parameters:
   Change from baseline at weeks 16 and 52
   Percentage of patients at treatment goals
Concurrent antihypertensive/lipid-lowering medication use
Safety and tolerability
Proactive intervention arm
(73 investigator sites,
779 patients)
Study drug dispensed
week 0
Inclusion
Cluster randomization
(140 investigator sites)
Intervention
Outcomes
Moderate CV risk patient population:
- 35 to 79 years old
- Hypertensiona  with ≥ 3 CV risk factors
- TC ≤ 6.5 mmol/L
- No CHD
UC control arm
(67 investigator sites,
682 patients)
Study drug dispensed
week 4
Study drug dispensed
week 16
Study drug dispensed
week 32
Study drug dispensed
week 52
Continued UC
week 0 to 52
Figure 1 Design of the CRUCIAL trial.
Notes: aHypertension, untreated: SBP $ 160 and/or DBP $ 100 mmHg; treated: SBP $ 140 and/or DBP $ 90 mmHg or diabetes: SBP . 130 and/or DBP . 80 mmHg.
Abbreviations: BP, blood pressure; CHD, congestive heart failure; Cv, cardiovascular; CvD, cardiovascular disease; DBP, diastolic blood pressure; LDL-C, low-density 
lipoprotein cholesterol; SCORE, Systematic COronary Risk Evaluation; SBP, systolic blood pressure; TC, total cholesterol; UC, usual care.
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Combining antihypertensive and antihyperlipidemic agents
There are a number of important requirements for therapies 
used in a combination medication, regardless of the condition 
being treated. Firstly, the medications must have a similar 
dosing regimen (eg, once- or twice-daily). Secondly, there 
should be no negative pharmacokinetic or pharmacodynamic 
interactions between the proposed components (eg, exacerba-
tion of adverse events [AEs] or other drug–drug interactions). 
Thirdly, from a patient’s perspective, the tablet should be of 
a reasonable size and the formulations should allow flexible 
dosing. The following section of this paper will review the 
evidence for whether or not the combination of amlodipine 
besylate and atorvastatin calcium fulfills these criteria.
Both amlodipine and atorvastatin can be administered 
once daily (they are effective for 24 hours) and food causes Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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no clinically meaningful variation in the bioavailability of 
either agent.35–37 The details of the pharmacokinetic proper-
ties of amlodipine and atorvastatin as individual agents have 
been described in detail in earlier reviews22,23,32,34,38 and will 
therefore not be discussed in detail in this paper. Two studies 
examining the pharmacokinetic properties of co-administered 
amlodipine and atorvastatin have been published. The first of 
these studies demonstrated that amlodipine does not affect the 
pharmacokinetic properties of atorvastatin, and vice versa, 
under fasting conditions.39 The second of these studies dem-
onstrated that the bioavailability of both agents is unchanged 
when they are administered with food.40 Therefore, the phar-
macokinetic properties of amlodipine and atorvastatin are 
well suited and are not a barrier to combining these agents 
into a single pill.
Two randomized, placebo-controlled clinical trials were 
undertaken to assess whether amlodipine affects the lipid-
lowering capacity of atorvastatin, and conversely to evaluate 
whether atorvastatin affects the BP-lowering efficacy of 
amlodipine, or if co-administration adversely affects the 
tolerability of either agent. The first of these studies, the 
Atorvastatin and Amlodipine in Patients with Elevated 
Lipids and Hypertension (AVALON) trial,41 conducted in 
848 patients from the USA and Canada, demonstrated that 
amlodipine co-administration with atorvastatin did not affect 
the BP-lowering efficacy of amlodipine. Co-administration 
of amlodipine 5 mg and atorvastatin 10 mg, however, led 
to a significantly greater effect on low-density lipoprotein 
cholesterol (LDL-C), total cholesterol (TC), and apolipopro-
tein B levels at week 8, compared with atorvastatin 10 mg 
alone. The AVALON study investigators mentioned that 
these observations were unexpected, and additional studies 
were needed to explore this further. The second of these two 
randomized, placebo-controlled clinical trials, Respond,42 was 
a larger trial than AVALON. Respond was conducted across a 
greater dose range for both amlodipine (placebo; amlodipine 
5 mg and 10 mg) and atorvastatin (placebo; atorvastatin 
10 mg, 20 mg, 40 mg, and 80 mg) than AVALON. In total, 
1660 patients from 15 countries were enrolled. This study 
demonstrated that atorvastatin did not affect the BP-lowering 
efficacy of amlodipine and similarly amlodipine did not affect 
the LDL-C lowering capacity of atorvastatin. There was also 
no evidence of a higher incidence or exacerbation of AEs in 
patients receiving both medications vs either agent alone in 
these two studies.41,42 Therefore, these studies demonstrated 
that there were no pharmacodynamic or pharmacokinetic 
barriers to combining amlodipine and atorvastatin into a 
single pill.
Indeed, there is some evidence that there might be some 
pharmacodynamic benefits associated with combining these 
agents. A wide variety of both preclinical and clinical studies 
has assessed the separate and combined effects of amlodipine 
and atorvastatin on cell systems, arterial wall compliance, and 
CV endpoints.43–45 Studies conducted using human umbilical 
vein endothelial cells to evaluate the effects of amlodipine 
and atorvastatin alone and in combination on nitric oxide 
(NO) release demonstrated that co-administered amlodipine 
and atorvastatin had a synergistic effect on increasing NO 
concentrations. This in turn reduced nitroxidative stress. 
Furthermore, co-administered amlodipine and atorvastatin 
partially restored NO levels following LDL-C–induced 
endothelial dysfunction.44 An AVALON substudy demon-
strated a 19% improvement in small artery compliance (C2) 
with co-administered amlodipine 5 mg and atorvastatin 
10 mg in patients with HTN and DYS from baseline to week 
8, which was significantly greater than with either amlodipine 
5 mg or atorvastatin alone or placebo.45 Moreover, a potential 
beneficial interaction between atorvastatin and amlodipine 
was suggested by the results of a pre-specified 2 × 2 facto-
rial analysis of data from the Anglo-Scandinavian Cardiac 
Outcomes Trial (ASCOT). Compared with placebo, the 
risk reduction of non-fatal myocardial infarction (MI) and 
fatal coronary heart disease (CHD) was greater in patients 
receiving an atorvastatin- plus amlodipine-based regimen 
than in those receiving an atorvastatin- plus atenolol-based 
regimen.43
SPAA tablets are available in a range of amlodipine/
atorvastatin doses from 2.5/10 mg to 10/80 mg. However, 
the doses approved vary from country to country with just 
5/10 mg and 10/10 mg available in some parts of Europe. 
SPAA pills are not particularly large and there have been no 
reports of the size of the SPAA being an issue for patients. 
Indeed, a small pilot study indicated that patients were satis-
fied with SPAA treatment in relation to their previous treat-
ment of HTN and DYS.46 This therefore suggests that the pill 
size is not a barrier to use and the dose strengths available 
enable flexible dosing.
Safety considerations  
and contraindications
Amlodipine and atorvastatin have been used in routine clini-
cal practice both alone and in combination for many years. 
Initial safety concerns surrounding the use of CCBs, which 
were based on the results of observational studies were not 
substantiated in a series of large randomized trials, which pro-
vided evidence on both the efficacy and safety of amlodipine Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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in a broad range of patients.11,12,28,47 Furthermore, clinical 
trials and meta-analyses have demonstrated that atorvastatin 
is an effective and well-tolerated medication.12,14,48,49 A ret-
rospective analysis of 49 clinical trials of atorvastatin dem-
onstrated that the overall incidence of treatment-associated 
AEs in patients receiving atorvastatin was similar to that in 
patients receiving placebo.49 Furthermore, many of the side 
effects associated with statins such as atorvastatin, tend to 
be dose related and often resolve when treatment is stopped 
or if the dose is reduced.22 Nevertheless, the safety consid-
erations for, and contraindications of, both amlodipine and 
atorvastatin need to be considered before prescribing these 
medications as SPAA.
In terms of contraindications, SPAA should not be 
used in patients with a known sensitivity to either amlo-
dipine or atorvastatin, or in women who are, or may 
become, pregnant or women who are breast feeding.37 
SPAA is also contraindicated in patients with active liver 
disease or unexplained persistent elevations in hepatic 
transaminases. Rare cases of rhabdomyolysis have been 
reported in patients treated with atorvastatin and other 
statins.   Therefore, patients should be advised to report 
promptly muscle pain, tenderness, or weakness to their 
physician. Patients with a history of renal failure, which 
can exacerbate the risk of muscle damage, should be 
closely monitored for rhabdomyolysis.37 Other factors that 
may predispose patients to myopathy are advancing age 
($ 65 years) and hypothyroidism. Treatment with SPAA 
should be temporarily withheld or discontinued if a patient 
develops myopathy or rhabdomyolysis. Furthermore, dos-
ing instructions should be followed carefully when SPAA 
is co-administered with fibric acid derivatives, niacin, 
cyclosporine, clarithromycin, itraconazole, or HIV protease 
inhibitors – medications that can increase the risk of myo-
pathy or rhabdomyolysis. Statins have also been associated 
with abnormalities in liver function.37 Therefore, it is rec-
ommended that liver function tests are undertaken before 
and 12 weeks after initiating therapy with, or increasing the 
atorvastatin component of, SPAA. If persistent elevations 
in liver enzymes occur, reduction in the dose of SPAA or 
withdrawal of SPAA is recommended.37
Caution is required when treating certain patient popu-
lations with SPAA. For example, elderly patients should 
initiate treatment at the low end of the dose range for 
amlodipine, and patients with hepatic impairment should 
have their dose titrated slowly.36 Furthermore, a potential 
worsening of angina and acute MI (particularly in patients 
with severe obstructive coronary artery disease) can develop 
on initiating amlodipine or increasing the dose of this 
medication.37 Caution is also advised when prescribing high 
doses of atorvastatin in patients with a recent stroke.35,37 
This advisory is based on a post hoc analysis of the Stroke 
Prevention by Aggressive Reduction in Cholesterol Levels 
(SPARCL) study.50 Patients in this study had no history of 
CHD but had a stroke or transient ischemic attack within 
the preceding 6 months. A higher incidence of hemorrhagic 
stroke was seen in the atorvastatin 80-mg group compared 
with placebo (2.3% vs 1.4%). Some baseline characteristics, 
including hemorrhagic and lacunar stroke on study entry, 
were associated with a higher incidence of hemorrhagic 
stroke in the atorvastatin group.
See the SPAA package insert for full details on the 
contraindications, precautions, and dosing requirements for 
SPAA.37
Treatment objectives:  
efficacy studies
Single-pill amlodipine/atorvastatin studies
The AVALON41 and Respond42 studies outlined above both 
used co-administered amlodipine and atorvastatin rather 
than SPAA. A variety of both open-label and randomized 
controlled studies has now been conducted to evaluate the 
efficacy and tolerability of SPAA. The first of these was the 
GEMINI trial, which was a 14-week, open-label trial con-
ducted in 1220 patients from the USA, which demonstrated 
that SPAA was well tolerated and could help patients with 
HTN and DYS achieve their BP and LDL-C goals.51 The 
subsequent GEMINI-Australia, Asia, Latin America, Africa/
Middle East (AALA) study, which was a very similar study 
design, confirmed the findings of GEMINI among 1649 
patients residing across Asia Pacific, the Middle East, Africa, 
and Latin America.52 The findings of these two studies were 
confirmed in the JEWEL study program, with JEWEL 1 
conducted among 1138 patients from the UK and Canada 
and JEWEL 2 conducted in 1107 patients from Europe.53 A 
further study on the use of SPAA in the USA, the Clinical 
Utility of Caduet in Simultaneously Achieving Blood Pres-
sure and Lipid End Points (CAPABLE54), was conducted in 
499 African American patients. CAPABLE examined the 
efficacy and safety of SPAA in a population that is rarely 
studied and has a high prevalence of HTN and mortality rates 
from CVD compared with other ethnic groups in the USA. 
In the CAPABLE trial, dual goal attainment was improved 
after 20 weeks of SPAA (48.3% patients achieved their BP 
and LDL-C goals vs 0.8% at baseline).Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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Taken as a whole, these studies demonstrate the clini-
cal utility and good tolerability profile of SPAA across 
patients with HTN and DYS alone as well as those with 
additional CV risk factors, diabetes/metabolic syndrome,55 
and symptomatic CVD.51,52,54,56 The data from GEMINI, 
GEMINI–AALA, JEWEL 1/2, and CAPABLE have been 
pooled and used to compare changes in BP when SPAA was 
used as first-line vs add-on antihypertensive treatment, and 
to investigate changes in LDL-C when SPAA was used as 
first-line vs replacement lipid-lowering treatment. Similar 
BP reductions were observed when SPAA was used as first-
line or add-on antihypertensive treatment. Although LDL-C 
reductions were greater when SPAA was used as first-line 
vs replacement lipid-lowering treatment, both groups were 
observed to have clinically beneficial lowering of LDL-C.57 
Data from this pooled analysis were also used to compare BP 
lowering and LDL-C reduction after treatment with SPAA 
in patients aged $ 75 years and , 75 years,58 and in men 
and women aged $ 65 years and , 65 years with HTN and 
DYS.59 The first of these analyses demonstrated that SPAA 
was similarly effective at lowering BP and LDL-C in patients 
aged $ 75 years and , 75 years,58 The second analysis indi-
cated that systolic BP reductions were similar but diastolic 
BP reductions tended to be greater in the older ($ 65 years) 
vs the younger (, 65 years) group in both men and women. 
In both age groups women tended to have higher baseline 
LDL-C and greater LDL-C reduction than men.59
In addition to the non-comparative open-label ‘real-
world’ GEMINI, GEMINI-AALA, JEWEL, and CAPABLE 
studies, two randomized, double-blind, placebo-controlled 
trials have also been conducted to evaluate the efficacy of 
SPAA. The first of these studies, CUSP (The Caduet® in an 
Untreated Subject Population trial),60 compared SPAA plus 
therapeutic lifestyle changes (TLC) with placebo plus TLC 
in 130 US patients with HTN and DYS but without CHD, 
who were not being treated with either antihypertensives or 
lipid-lowering agents. Significantly more patients receiv-
ing SPAA and TLC reached both BP and LDL-C goals 
at study end compared with TLC and placebo (55.6% vs 
5.0%). The second of these studies, the TOGETHER trial, 
evaluated whether targeting multiple CV risk factors with 
SPAA (5/20–10/20 mg) and TLC resulted in greater BP/lipid 
control and additional reduction in CVD risk in comparison 
with amlodipine (5–10 mg) plus TLC in patients with HTN 
and additional CV risk factors (but not CVD or diabetes).61 
At the end of this 6-week study, significantly more patients 
receiving SPAA reached both BP and LDL-C goals compared 
with patients receiving only amlodipine (67.8% vs 9.6; odds 
ratio [OR]: 19.0; 95% confidence interval [CI]: 9.1–39.6; 
P , 0.001).61
The CRUCIAL study
The CRUCIAL study is the only long-term randomized 
comparative trial of SPAA.21 CRUCIAL was a 12-month, 
international, multicenter, prospective, open-label, parallel 
design, cluster-randomized trial conducted in 19 countries 
in four geographical regions, including Asia, the Middle 
East, Europe, and Latin America, between March 2007 and 
October 2009 (Figure 1). CRUCIAL was the first study 
designed to investigate whether a proactive multifactorial 
risk factor intervention strategy using SPAA (based on SPAA 
[5/10, 10/10 mg] plus continuing usual care [UC]) resulted 
in greater reduction in calculated Framingham 10-year CHD 
risk compared with UC alone.
A total of 1461 patients aged 35–79 years with HTN 
(untreated or treated), TC # 6.5 mmol/L (untreated), and 
three or more additional CV risk factors, with or without 
diabetes but without CHD, were enrolled and received treat-
ment. Investigators randomized to the proactive intervention 
strategy arm initiated their patients on SPAA at 5/10 mg to 
10/10 mg and, if approved in the participating country, this 
was increased to 5/20 mg and 10/20 mg. In the UC arm, the 
investigator had the full choice of any locally approved (and 
not contraindicated) antihypertensive and/or lipid-lowering 
drugs based solely on the investigators’ clinical judgment, 
including, but not limited to, amlodipine, atorvastatin, or 
SPAA.
The primary efficacy endpoint was the calculated 10-year 
risk of developing CHD at 52 weeks using a Framingham 
CHD model.62 Secondary efficacy endpoints included post-
baseline changes in BP and lipids, BP and LDL-C goal 
attainment, and additional measures of CHD or CVD risk 
such as the European SCORE 10-year risk of CV mortality,63 
the 10-year Framingham risk for fatal and non-fatal CVD,64 
and the Framingham stroke risk.65
The proactive intervention strategies with SPAA and 
UC treatment arms were well matched for gender (53.4% 
vs 50.5% male), age (60.0 vs 60.3 years), and race (white 
45.8% vs 47.6%; Asian 34.9% vs 36.2%). At baseline, LDL-C 
levels were similar (119.4 vs 118.0 mg/dL) in the two treat-
ment arms. BP, however, was higher at baseline in the proac-
tive intervention strategy than in the UC arm (systolic BP 
150.3 vs 144.3 mmHg and diastolic BP 89.7 vs 86.5 mmHg, 
respectively). This led to a higher calculated baseline absolute 
Framingham 10-year CHD risk in the proactive interven-
tion strategy compared with the UC arm (20.0% vs 18.1%). Integrated Blood Pressure Control 2011:4
Screening Week 16 Week 52
0
20
40
60
80
100
Proactive intervention arm  (n = 760) UC control arm (n = 657)
Antihypertensive
drugsa
Lipid-lowering
drugsa
95.0%
97.0%
91.8%
85.1%
5.3%
30.8% 31.7%
3.3% 5.9% 6.1%
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
(
%
)
86.1%
97.1%
Figure 2 Concurrent antihypertensive and lipid-lowering medication use at screening and at weeks 16 and 52 in the CRUCIAL trial.
Notes: aIn the proactive intervention arm these are antihypertensive and lipid-lowering medications in addition to SPAA; in the UC arm these are the total number of 
antihypertensive and lipid-lowering medications.
Abbreviations: SPAA, single-pill amlodipine/atorvastatin; UC, usual care.
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The reasons for the difference in BP between the treatment 
arms at baseline are uncertain. However, it is possible that 
they are related to the cluster randomization used in this study 
in which the investigators rather than the patients were ran-
domized. The following precautions were taken to balance the 
treatment arms for potentially confounding factors. Firstly, 
patients were enrolled into the study before the investigators 
were randomized to avoid patient selection bias. Secondly, 
study investigators were randomized in a 1:1 ratio within each 
country. Post-baseline evaluations of CHD, CVD or stroke 
risk, and BP were adjusted to account for these differences 
in BP and Framingham CHD risk at baseline.
The majority of patients in the proactive intervention strat-
egy arm were taking antihypertensives in addition to SPAA 
(85% at week 16 and 86% at week 52), but few patients were 
taking additional lipid-lowering agents (5.9% at week 16 and 
6.1% at week 52; Figure 2). The mean dose of SPAA at study 
endpoint was amlodipine 6.5 mg/atorvastatin 11.0 mg. In the 
UC arm nearly all patients received antihypertensives (97% at 
week 16 and 97% at week 52) with a mean (SD) of  2.5 (1.3) and 
2.6 (1.4) antihypertensive medications per patient at weeks 16 
and 52. Less than one third of patients in the UC arm received 
lipid-lowering therapy (31% at week 16 and 32% at week 52). 
This was despite the benefits of lipid-lowering therapy previ-
ously observed in this patient population in ASCOT-LLA.12
At study endpoint (week 52), mean absolute Framingham 
CHD risk was 12.5% in the proactive intervention strategy 
arm and 16.3% in the UC arm (P , 0.001), which repre-
sented a relative risk reduction of –33.0% vs –4.0%. Other 
measures of CVD and stroke risk were similarly reduced to 
a much greater extent in the proactive intervention strategy 
vs the UC arm (Figure 3). It should be recognized that 
estimated CHD, CVD, or stroke risk are all surrogates for 
hard CV endpoints that have not been validated for assess-
ing the impact of BP or lipid-lowering medications on CV 
endpoints.21 However, both amlodipine and atorvastatin have 
been demonstrated to reduce hard CV endpoints in a clinical 
trial with similar patient inclusion and exclusion requirements 
to CRUCIAL.12,29,43
The mean absolute BP reductions from baseline at week 
52 in the proactive intervention arm and the UC arm were 
–19.8 vs –10.0 mmHg (systolic) and –10.5 vs –5.3 mmHg 
(diastolic), respectively (Figure 4). The mean relative LDL-C 
reduction from baseline at week 52 in the proactive interven-
tion arm was 25.6%, whereas LDL-C increased by 2.7% in 
the UC arm (Figure 4). These substantial reductions in both 
BP and LDL-C in the proactive intervention arm using SPAA 
were driving the fall in estimated CHD, CVD, and stroke 
risk (Figure 3).
Attainment of Joint National Committee on the pre-
vention, detection, evaluation, and treatment of high 
blood pressure 7: (JNC 7) BP goals8 was slightly higher 
in the proactive intervention vs the UC arm at week 16 
(49% vs 46%; OR: 1.08; 95% CI: 0.79–1.48; P = 0.618) Integrated Blood Pressure Control 2011:4
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weeks 16 and 52 in the CRUCIAL trial.
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Figure  3  Percentage  change  in  calculated  10-year  (A)  Framingham  CHD  risk, 
(B) European SCORE fatal Cv risk, (C) Framingham fatal and non-fatal CvD risk, 
(D) Framingham stroke risk from baseline to week 16 and 52, by treatment arm in 
the CRUCIAL trial.
Note: aP , 0.001.
Abbreviations: CHD, coronary heart disease; CI, confidence interval; CRUCIAL, 
Cluster Randomized Usual Care vs Caduet Investigation Assessing Long-term-risk; 
Cv, cardiovascular; CvD, cardiovascular disease; LS, least squares; SCORE, Systematic 
COronary Risk Evaluation model; UC, usual care.
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and this increased to 58% vs 48% (OR: 1.59; 95% 
CI: 1.15–2.2; P , 0.001) at week 52. Attainment of the 
National   Cholesterol Education Program (NCEP) expert 
panel on detection, evaluation, and treatment of high 
blood   cholesterol in adults (Adult Treatment Panel III) 
(NCEP ATP III)7 LDL-C goals was markedly higher in 
the proactive intervention vs the UC arm at both week 16 
(88% vs 53%; OR: 7.1; 95% CI: 5.17–9.73; P , 0.001) 
and week 52 (83% vs 53%; OR: 4.39; 95% CI: 3.31–5.82; 
P , 0.001). Dual BP/LDL-C goal attainment was also 
achieved in a significantly higher proportion of patients in 
the proactive intervention using SPAA vs the UC arm at 
both week 16 (43% vs 26%; OR: 2.1; 95% CI: 1.56–2.90; 
P , 0.001) and week 52. (50% vs 27%; OR: 2.83; 95% 
CI: 2.11–3.90; P , 0.001).Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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The evaluation of AEs in CRUCIAL was complicated 
by the fact that only patients in the proactive intervention 
arm received study medication (SPAA). Patients in the UC 
arm continued their existing antihypertensive and lipid-
lowering medications, which were presumably well tolerated 
in that they had not been discontinued due to AEs or other 
safety concerns before entering the study. Most AEs in both 
treatment arms were mild to moderate in intensity. However, 
more patients discontinued their treatment due to AEs in the 
proactive intervention (6.7%) than in the UC arm (0.6%). The 
most commonly reported AEs in the proactive intervention 
arm were peripheral edema (6.8%), headache (3.0%), and 
nasopharyngitis (2.8%) in comparison with headache (2.2%), 
bronchitis (2.2%), and upper respiratory tract infection 
(2.1%) in the UC arm. There were no treatment-related 
deaths in either treatment group. The incidence of AEs in 
the proactive intervention arm was similar to that previously 
observed for SPAA52 and co-administered amlodipine and 
atorvastatin.42
A number of sub-analyses of the CRUCIAL study have 
been undertaken, with more planned in the future. In the 
first of these sub-analyses, the efficacy and tolerability of 
the proactive intervention strategy vs UC was assessed in 
patients with (n = 600) and without (n = 817) diabetes.66 The 
reductions in Framingham CHD risk and BP in patients in 
the proactive intervention arm vs UC were similar in those 
with and without diabetes. The SPAA-based treatment 
in the proactive intervention arm was well tolerated in 
patient groups, in line with previous studies.51,52 A similar 
evaluation assessing the proactive intervention arm resulted 
in a greater reduction in calculated Framingham 10-year 
CHD risk, BP, or LDL-C compared with continuing UC in 
younger (, 65 years) and older ($ 65 years) patients. This 
sub-analysis demonstrated that reductions in Framingham 
10-year CHD risk, systolic BP, and lipids in the patients in the 
proactive intervention arm vs UC were similar in both older 
and younger patients, and SPAA-based treatment was well 
tolerated.67 However, in patients treated with the proactive 
intervention vs UC, the reductions in diastolic BP were higher 
for younger than older patients.
Additional sub-analyses evaluating the efficacy and 
safety of the proactive intervention in comparison with UC 
in Pacific-Asian vs non-Pacific-Asian patients have been 
undertaken.68 A separate evaluation of the Pacific-Asian 
patients from the CRUCIAL population has compared 
baseline and endpoint CV risk estimations, made using 
the Japanese NIPPON DATA8069 risk assessment chart 
(which is based on Japanese longitudinal CV data), with 
the Framingham and SCORE risk assessments.70 A further 
analysis evaluating efficacy and safety of the proactive 
intervention in comparison with UC in Latin American vs 
non-Latin American patients is also underway.
In conclusion, the CRUCIAL study demonstrated that a 
proactive intervention strategy based on SPAA had substantial 
benefits on estimated CHD/CVD risk, BP, and lipids over 
continued UC in patients with HTN, TC # 6.5 mmol/L 
(untreated), and three or more additional CV risk factors, 
with or without diabetes but without CHD.
Health outcome  
and pharmacoeconomic studies
The results of the CRUCIAL trial clearly demonstrate the 
benefits of SPAA-based treatment vs UC within the controlled 
environment of a clinical trial. A broad range of observational 
studies has evaluated the effectiveness of SPAA in the 
real-world setting and the potential benefits of the use of 
SPAA in comparison with co-administered   amlodipine and 
atorvastatin. Furthermore, a pharmacoeconomic evaluation 
using transition probabilities and costs from the ASCOT 
study indicated that the combination of amlodipine-based 
therapy and atorvastatin was cost-effective in patients with 
similar characteristics to those enrolled in CRUCIAL (HTN 
and three or more additional risk factors but no CHD).71 
However, additional studies evaluating the costs of SPAA vs 
potential cost savings related to the benefits of this medication 
on CV endpoints in the real-world setting are required to 
confirm these findings.
One of the key reasons for combining two or more 
agents into a single pill is that it reduces pill burden and 
thus simplifies a patient’s treatment regimen, which can 
in turn improve patient adherence.72 This has important 
implications because improvement in patient adherence 
may increase therapeutic goal attainment, and in the long 
term improve health outcomes and reduce CV events.73,74 
Conversely, poor adherence to antihypertensive and 
lipid-lowering therapies can substantially reduce the 
effectiveness of these medications.75–79 For example, 
hypertensive patients taking antihypertensive and statin 
therapy at real-world adherence levels can be expected to 
receive only approximately 50% of the potential benefit 
demonstrated in clinical trials.78
Given the importance of adherence to medications 
that lower CV risk and the potential adherence benefits of 
single-pill combination medications over co-administered 
therapies,72 several studies have assessed predictors of 
adherence and nonadherence to antihypertensive and Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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lipid-lowering medications (Table 1). These studies have 
provided information on the factors that may play a role in 
driving the improved adherence to single-pill combination 
medications. The first of these studies evaluated adherence 
to antihypertensive and lipid-lowering medications in 8406 
patients with HTN newly initiated on these medications.80 
Adherence to antihypertensive and lipid-lowering medications 
was very low, just 36% of patients remaining adherent to 
both classes of medication at 12 months (Table 1). This 
study also suggested that increasing pill burden could 
decrease adherence80 and that patients were more likely 
to be adherent to their antihypertensive and lipid-lowering 
therapy if they initiated antihypertensive and lipid-lowering 
medications together, or had symptomatic CVD (Table 1).80 
The relationship between pill burden and adherence was 
assessed in more detail in a later study, which confirmed that 
adherence decreases as the number of medications a patient 
was taking increased (Table 1).81 The effect of the timing of 
antihypertensive and lipid-lowering medication initiation 
was studied in more detail in a subsequent study, which 
confirmed that synchronized initiation of these two classes 
of therapy improves adherence compared with initiating them 
separately (Table 1).82
All of the above retrospective database studies dem-
onstrated that overall adherence to antihypertensive and 
lipid-lowering medications is low, falling to just ∼30%–40% 
at 12 months after initiating therapy (Table 1).80,82 This there-
fore suggests that interventions to maintain and improve 
adherence to these medications over time are required. 
The effectiveness of interventions designed to improve   
adherence has been evaluated, and was identified in two 
systematic literature reviews.83,84 The first of these reviews 
identified a range of interventions that had successfully 
improved adherence to antihypertensive or lipid-lowering 
medications, such as fixed-dose combinations, unit-dose 
packaging, educational telephone calls, case management 
by pharmacists or nurses, and mailed refill reminders.83 The 
second evaluation extended and updated the first review, 
by additionally comparing the effectiveness and costs of 
interventions to improve adherence to antihypertensive and 
lipid-lowering therapies.84 Effectiveness was measured as 
relative improvement (RI) in adherence, which was defined 
as the ratio of adherence in the intervention group to the 
control group. The control group comprised patients taking 
antihypertensive and lipid-lowering therapies alone without 
any intervention program. Costs were calculated based on 
those reported in the analysis, if available, or estimated 
based on resource use described in each publication and 
using standard costs derived from the literature. Across five 
eligible studies, RI in adherence ranged from 1.11 for mailed 
refill reminders to 4.65 for case management by a commu-
nity pharmacist. The costs of interventions over 6 months 
ranged from US$10 per patient for monthly mailed remind-
ers to US$142 per patient for a combination of increased 
pharmacy care, and the use of patient diaries and educational 
material. In general, the more costly and time-consuming 
interventions were the most effective. However, across most 
healthcare systems it is unlikely that there will be sufficient 
resources available to provide intensive case management 
for all patients nonadherent to their antihypertensive and 
lipid-lowering medications.
Adherence benefits of single-pill  
amlodipine/atorvastatin
The use of fixed-dose combination medications has been 
shown to be an effective approach to improving patient 
adherence to therapies across a diverse range of disease areas, 
such as HTN, tuberculosis, HIV , and diabetes.72 The Caduet 
Adherence Research Program and Education (CARPE) 
retrospective cohort studies were designed to evaluate 
potential adherence benefits of SPAA vs co-administered 
antihypertensive and lipid-lowering therapy in real-world 
settings (Table 1).
The first of these studies, CARPE-Patient Benefits 
Management (CARPE-PBM), was a retrospective database 
study of pharmacy claims data that identified patients who 
were newly initiated on SPAA, or a CCB or statin (either 
simultaneously or within 30 days of each other). At 6-month 
follow-up, and after adjustments for differences between the 
cohorts, patients prescribed SPAA were significantly more 
likely to achieve adherence vs two-pill regimen amlodipine 
plus atorvastatin (OR: 1.95; 95% CI: 1.80–2.13).85
The CARPE-M study provided further insight into the 
potential adherence benefits of SPAA, by investigating the 
impact of prior CCB and statin use on adherence to SPAA. 
Although this study supported the finding of CARPE-PBM 
(higher adherence in patients receiving SPAA vs those 
receiving a two-pill regimen), CARPE-M also suggested that 
patients with prior experience of either CCB or statin use (but 
not both) were more likely to adhere to their SPAA treatment 
compared with treatment-naïve patients or those who had 
previous experience with both of these therapies (Table 1).86
A similar study was undertaken to see if adherence to 
antihypertensive therapy can be used to promote adherence Integrated Blood Pressure Control 2011:4
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Figure 5 Kaplan–Meier analysis of days to Cv event in patients receiving SPAA and co-administered CCB and statin.
Abbreviations: CCB, calcium channel blocker; Cv, cardiovascular; SPAA, single-pill amlodipine/atorvastatin.
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to statin therapy.87 This study question was addressed by 
evaluating adherence to statin therapy in hypertensive patients 
taking amlodipine switching to SPAA in comparison with 
patients adding a separate statin to their amlodipine regimen. 
At 6-month follow-up, patients who switched to SPAA were 
more likely to be adherent and to persist with their therapy 
than those adding a statin (Table 1).
The last study in this series, CARPE-M events examined 
whether improving adherence to SPAA was associated with 
a lower risk of CV events in patients with HTN but no prior 
history of CV events.74 The primary measure in this study 
was the rate of CV events from 6 to 18 months following 
the initiation of antihypertensive therapy. The CV event rate 
was compared in three ways: (1) all adherent vs nonadherent 
patients; (2) SPAA vs two-pill therapy (CCB/statin patients 
regardless of adherence level); and (3) adherent SPAA, adher-
ent two-pill, and nonadherent SPAA patients vs nonadherent 
two-pill patients. After 6 months of treatment, 56.5% of the 
1537 SPAA patients were adherent vs 21.4% of the 17,910 
two-pill therapy patients (OR: 4.7; P , 0.001). For compari-
son (1), of all adherent vs nonadherent patients, remaining 
adherent to therapy was associated with significantly lower 
risk of CV event (hazard ratio [HR]: 0.77; P = 0.003). SPAA 
was also associated with fewer CV events when differences 
in adherence were not factored in (HR: 0.68; P = 0.02). As 
a result of improved adherence, patients prescribed SPAA vs 
two-pill CCB plus statin therapy had significantly longer time 
to CV event (Figure 5). For comparison (3), when adherence 
was included as a covariate, the strength of association was 
reduced. The risk of CV events was significantly lower 
for adherent CCB/statin patients (HR: 0.79; P = 0.01) and 
adherent SPAA patients (HR: 0.61; P = 0.03) compared 
with patients nonadherent to two-pill therapy (CCB/statin 
patients), suggesting differences in adherence may play a 
role in SPAA’s observed benefit.
Some limitations to these real-world evaluations should 
be taken into account. All of these studies were conducted 
in the USA and the results may not be directly applicable 
to other geographical regions due to differences in   clinical 
practice between healthcare systems or the prevalence 
of CV comorbidities in other parts of the world. Further 
  studies are therefore warranted in other patient populations 
to determine the beneficial effect of SPAA on adherence and 
CV outcomes, reported in these retrospective US studies.
Patient satisfaction/patient acceptability
There is increasing evidence that patient satisfaction 
with therapy improves adherence88,89 and, conversely, that 
patient dissatisfaction leads to poor adherence.90 Therefore, 
medications that improve patient satisfaction may contribute 
towards improving health status, lowering healthcare use, 
shortening hospital stays, and improving continuity of care. Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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Patient satisfaction is therefore an important aspect of a 
patient’s treatment regimen. Patient satisfaction with SPAA vs a 
multiple-pill regimen was investigated in some pilot studies. The 
Expectations and Satisfaction with Treatment Questionnaire 
(ESTQ) was developed through patient focus groups and 
clinician interviews as a tool to determine patients’ expectations 
for, satisfaction with, and adherence to treatment for HTN 
and DYS. This questionnaire was originally tested during 
the AVALON study41 and later modified to the ESTQ short 
form (ESTQ-SF).46 Using data from the JEWEL program,46,56 
SPAA treatment was shown to increase patient satisfaction 
vs a multiple-pill regimen.46 Due to the preliminary nature of 
these data, further study is needed before firm conclusions can 
be drawn on whether an increase in patient satisfaction with 
SPAA contributes to the improved adherence observed with 
SPAA vs multiple-pill regimens.
Conclusion
Much of the proposed benefits of the PolypillTM can be achieved 
through reducing BP and LDL-C. There is now a wealth of 
preclinical, clinical, and outcomes research data supporting 
the use of a combination of amlodipine and atorvastatin into 
a single-pill therapy. The recently completed CRUCIAL trial 
conducted in patients with HTN and three or more additional 
CV risk factors but no CHD demonstrated that a SPAA-based 
proactive intervention strategy can improve BP and LDL-C 
goal attainment and reduce calculated CV risk in comparison 
with UC alone. Taken together, these findings suggest that 
SPAA can play an important role in helping physicians improve 
the management of CV risk in their patients.
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